-- Achieved $92.5 million in AYVAKIT net product revenues in the first quarter 2024 -- -- Raising guidance to $390 million to $410 million in full year AYVAKIT net product revenues -- -- Strengthening presence in allergy and inflammation with the IND for wild-type KIT inhibitor BLU-808 on track for filing in Q2 -- CAMBRIDGE, Mass., May 2, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today reported financial results, provided a business update for the first quarter ended March 31, 202 ...

­-- Dr. Mariana Castells, M.D., Ph.D., a renowned researcher and clinical expert in mast cell diseases, will join members of Blueprint Medicines' management team to provide a perspective on the mast cell as a promising target for treating allergic and inflammatory disease on April 25, 2024, at 10:00 a.m. ET -- -- First in a series of planned webcasts hosted by Blueprint to highlight evolving science around R&D and pipeline strategy -- CAMBRIDGE, Mass., April 11, 2024 /PRNewswire/ -- Blueprint Medicines Corp ...

-- AYVAKIT data in patients with indolent systemic mastocytosis show durable efficacy and favorable safety supporting long-term treatment, consistent with real-world experience observed in commercial setting -- -- Preclinical data for BLU-808, a highly selective and potent oral wild-type KIT inhibitor with best-in-class potential, supports development in chronic urticaria and other mast cell diseases; on track to submit IND to FDA in Q2 2024 -- -- Breadth of data across 9 presentations, including 2 oral, hi ...

Blueprint Medicines (BPMC) reported $71.96 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 85.6%. EPS of -$1.82 for the same period compares to -$2.65 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $67.28 million, representing a surprise of +6.95%. The company delivered an EPS surprise of +10.78%, with the consensus EPS estimate being -$2.04.While investors closely watch year-over-year changes in headline numbers -- revenue and e ...

Blueprint Medicines Corporation (BPMC) reported a fourth-quarter 2023 loss of $1.82 per share, narrower than the Zacks Consensus Estimate of a loss of $2.04 and a loss of $2.65 in the year-ago quarter.Quarterly revenues of $72.0 million also surpassed the Zacks Consensus Estimate of $67.3 million. Revenues rose 85.5% year over year.Quarter in DetailBlueprint’s total revenues comprise net product revenues from Ayvakit/Ayvakyt and collaboration revenues.Ayvakit (avapritinib), an inhibitor of KIT and PDGFRA pr ...

Blueprint Medicines Corporation (NASDAQ:BPMC) Q4 2023 Earnings Conference Call February 15, 2024 8:00 AM ET Company Participants Jenna Cohen - Vice President, Investor Relations Kate Haviland - Chief Executive Officer Philina Lee - Chief Commercial Officer Suad Namouni - President of Research and Development Christy Rossi - Chief Operating Officer Mike Landsittel - Chief Financial Officer Becker Hewes - Chief Medical Officer Conference Call Participants Brad Canino - Stifel Salveen Richter - Goldman Sachs ...

Blueprint Medicines (BPMC) came out with a quarterly loss of $1.82 per share versus the Zacks Consensus Estimate of a loss of $2.04. This compares to loss of $2.65 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 10.78%. A quarter ago, it was expected that this cancer drug developer would post a loss of $2.39 per share when it actually produced a loss of $2.20, delivering a surprise of 7.95%.Over the last four quarters, the com ...

Table of Contents Form 10-K BLUEPRINT MEDICINES CORPORATION (Exact name of registrant as specified in its charter) Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☑ No ☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☑ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securit ...

Wall Street analysts forecast that Blueprint Medicines (BPMC) will report quarterly loss of $2.04 per share in its upcoming release, pointing to a year-over-year increase of 23%. It is anticipated that revenues will amount to $67.28 million, exhibiting an increase of 73.5% compared to the year-ago quarter.Over the last 30 days, there has been an upward revision of 0.1% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideratio ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Blueprint Medicines (BPMC) reports results for the quarter ended December 2023. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on February 15, 2024, might help the stock move higher if these key numbers are bet ...